Primary Peritoneal Carcinoma Not Yet Recruiting Phase 1 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03283943PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.Treatment